To animate the Banner
Talent Recruitment
Apply for post
Recruitment Position
Place of work
Number of Recruits
Salary Treatment
Obutinib
Obitinib (trade name: Yinokai) is a highly selective new BTK inhibitor independently developed by Nuo Cheng Jianhua. As a new BTK inhibitor, Obitinib has an innovative compound structure, resulting in high selectivity, reduced off-target effects, and better efficacy and safety. Obutinib has been approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL) in China in 2020, incorporated into the national health insurance in 2021 and approved for listing in Singapore in 2022. The latest data showed an ORR of 83% for orbutib in relapsed/refractory MCL, with a complete response rate (CR) of 36.8. More data can be found in an article published in Blood Advances, a sub-journal of Blood. MCL is a subtype of B- cell non-Hodgkin lymphoma caused by malignant transformation of B lymphocytes in the follicular mantle region of the lymph node. Despite the high response rate after first-line blood immunotherapy, most patients relapse and require subsequent treatment. There is no standard therapy for relapsed/refractory MCL, and the US Food and Drug Administration (FDA)-approved therapies for this patient remain limited, with low rates of complete remission, short duration of remission, and poor safety and tolerability in older patients. Obutib has been included in the Chinese Society of Clinical Oncology (CSCO) "2021 Guidelines for the Diagnosis and Treatment of Malignant Lymphoma", has been listed as a first-class recommend regimen for the treatment of relapsed/refractory MCL, and has won many innovative awards.
Focus on us
Contact Information
Monday to Friday 9:00~17:00
Rooms 801-808 and 901-908, Building H, No. 3 Jiu Quan Road, Huangpu District, Guangzhou City
Copyright©2024 Virotech Pharmaceutical Technology Co., Ltd.
